Clinical Trial Update: Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating dual EGFR inhibition with cetuximab and afatinib for refractory wild-type KRAS metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gilotrif (Afatinib)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED